NASDAQ NMS - GLOBAL MARKET · APLM
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
Apollomics Inc

Apollomics Inc

Biotechnology
$21.78
Card
Relationship Map

Follow $APLM

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $APLM by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
APLM
Apollomics Inc
Thu Oct 8 · last completed session · Pre-market · regular session opens 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

62/ 100
Veridion Score
Upper range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4 of 6 factors measured · Thu Oct 8 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is APLM moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading APLM catalysts
About Apollomics Inc
Biotechnology
Listed since
2023
Employees
15
Country
US

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$21.78
Last session
Day high
$21.78
Last session
Day low
$21.78
Last session
Previous close
$21.78
52W high
$36.65
-40.57% from high
52W low
$11.61
41% of range
Market cap
$63.5M
EPS
$-18.9295
Beta
0.51
Shares out
2.9M
Avg volume
9.4K
VWAP
$21.78
Last session
Price history computed in-house
1W
-6.39%
1M
-12.46%
3M
+14.93%
YTD
+16.50%
SMA 50 $22.51 · below
SMA 200 $18.79 · above
52W position 41%

APLM overview

Veridion Score
62
Registered · 2026-10-08
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around APLM.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading APLM Form 4 filings
Public disclosures

Congress activity in APLM

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

APLM contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for APLM in this window.
Lobbying spend

APLM lobbying filings, year to date.

Registered lobbying filings matched to Apollomics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for APLM in this window.
Loading news for APLM
Analyst ratings
Sovereign unlock shows live analyst consensus for APLM.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.